tions, standardized quality-of-life questionnaire results, and Kaplan- Meier estimates of 5-year biochemical progression-free survival (PFS) between the groups. RESULTS: RARP required a longer operative time than RRP (215 minutes vs 202 minutes, p0.0001), but demonstrated lower intraoperative blood loss (200 cc vs 450 cc, p0.0001) and shorter length of hospital stay (1 vs 2 days, p0.0001). Positive margin rates were higher for the RARP group (14.6% vs 11.7%, p=0.02), but this difference was not observed with greater surgeon experience (50-100 cases; p=0.53, 100-500 cases; p=0.18). The occurrence of any intra- operative complication was higher in the RRP group (1.0% vs 0.7%, p=0.02), although early (30 day) complication rates were higher in the RARP group (7.3% vs 5.3%, p=0.02). In particular, early hernia (0.7% vs 0.1%, p=0.01) and urinary retention requiring catheterization were more common with RARP (3.1% vs 1.8%, p=0.02), while early pulmonary embolus (PE) and lymphocele were more common with RRP (0.6% vs 0.1%, p=0.03 and 2.3% vs 0.5%, p=0.0001, respec- tively). Late hernia was more common in the RARP group (5.4% vs 3.8%, p=0.045) while late bladder neck contracture and late PE were more common with RRP (4.3% vs 1%, p0.0001 and 0.4% vs 0%, p=0.01, respectively). One year postoperatively, there was no differ- ence in continence between the techniques (RARP 93% vs RRP 93%; p=0.93). Meanwhile, a higher proportion of men in the RARP group were potent at 1 year (74.5% vs 67%, p=0.0005). Also, no difference in 5-year PFS was noted (RARP 91% vs RRP 89%; p=0.26). CONCLUSIONS: RARP was noted to have a higher early complication rate, primarily consisting of hernia and urinary retention. The higher rate of margin positivity seen with RARP was eliminated with increasing surgeon experience. Continence rates at one year were similar between groups, while potency rates were higher with RARP. RRP and RARP are associated with equivalent short-term oncologic outcome. Source of Funding: None 1810 ANALYSIS OF BIOCHEMICAL RECURRENCE BEYOND 5 YEARS AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY Bertram Yuh*, Clayton Lau, Nora Ruel, Mark Kawachi, Timothy Wilson, Duarte, CA INTRODUCTION AND OBJECTIVES: Long-term analysis of prostate cancer treatment is important to determine the lasting effect of therapy. There is a lack of long-term data regarding biochemical free survival in patients undergoing robot-assisted radical prostatectomy. METHODS: Between 2003 and 2006, 1663 patients with clini- cally localized adenocarcinoma of the prostate underwent robot-as- sisted radical prostatectomy. 401 (24.1%) had follow-up of greater than 60 months. Median length of follow-up was 71 months (range 60-96). The cohort of 401 patients had a higher D’amico risk stratification, higher Gleason score, pathologic stage, and node positive rate com- pared to the rest of the patients. Biochemical recurrence was defined as any serum PSA  .2 ng/ml following prostatectomy allowing 42 days for nadir. Biochemical free survival was calculated over the study period using Kaplan-Meier survival analysis. RESULTS: Median age of patients was 64 years, 89% were Caucasian, and median BMI was 28. 50% of patients were classified as low-risk according to D’Amico criteria and 50% were intermediate or high-risk. Median operative time was 2.7 hours with median estimated blood loss of 200 ml(range 25-1500). Overall complication rate was 14%. 19% of patients were pathologic stage T3 or above with 1.7% of patients having lymph node positivity. Positive margin rate for the entire group was 24%. Overall, 2-year and 5-year biochemical free survival for the cohort was 91% and 85% respectively. On multivariate analysis, Gleason score (p.0001) and positive surgical margin (p=.04) were associated with biochemical recurrence. CONCLUSIONS: Robot-assisted radical prostatectomy is as- sociated with long-term biochemical free survival that is comparable to radical retropubic prostatectomy. This contemporary series demon- strates durable oncologic control and safety. Source of Funding: None 1811 ASSESSMENT OF REQUIRED NODAL YIELD FOR ACCURATE STAGING IN A HIGH RISK COHORT UNDERGOING EXTENDED LYMPHADENECTOMY IN ROBOT-ASSISTED RADICAL PROSTATECTOMY AND THE IMPACT ON FUNCTIONAL OUTCOMES Dan Sagalovich*, Adam Calaway, Abhishek Srivastava, Bilal Chughtai, Prasanna Sooriakumaran, Matthieu Durand, Siobhan Gruschow, Danielle Brooks, Alexandra Peyser, Bekheit Salamoon, Robert Leung, Brian Robinson, Maria Shevchuk, Ashutosh Tewari, New York, NY INTRODUCTION AND OBJECTIVES: To establish a minimal lymph node (LN) yield necessary for accurate staging in a high risk cohort. Also, to investigate the impact of an extended pelvic lymph node dissection (ePLND) on urinary and sexual function. METHODS: Our cohort consisted of 760 patients who under- went robot-assisted radical prostatectomy (RARP) from January 2010 – June 2011 by a single surgeon. Low and intermediate D’Amico risk groups underwent a minimum of a limited PLND (obturator/external iliac packets); high risk patients underwent an ePLND (additional hy- pogastric nodes up to the common iliac bifurcation). To analyze LN yield for staging purposes, the D’Amico high-risk group (n=82) was subdivided into patients with 13 LN yield versus 13 LN. The inci- dence of LN invasion was compared between these groups. To study the impact of ePLND on functional outcomes, we included patients from our total cohort who were preoperatively potent (SHIM 17) and continent, and who received bilateral nerve-sparing surgery. Return to potency at 26 weeks postoperatively was defined as score of 3 on questions 2 and 3 of the SHIM questionnaire. Continence was defined as 0 pads/day or 1 security liner/day. RESULTS: Median LN yields in the low, intermediate, and high risk groups were (IQR): 5 (2-10), 7 (3-12), and 13 (6-20) (p0.001). LN positivity was 0% (0 of 309), 0.8% (3 of 369), and 13.4% (11 of 82) in the 3 risk groups (p0.001). Median LN (IQR) yields among the high risk LN positive and negative patients were 20 (13-22) and 11 (5-18) (p=0.05). 5% of the patients had positive LNs in the 13 LNY group vs. 21% of patients in the 13 LNY group (p=.036). Median console time was significantly different at 120 min (95-137) for 13 LN group and 100 min (85-120) for 13 LN group (p=0.04). Among patients who fit the inclusion criteria for functional outcomes (n=384), 63.6% (14 of 22) with 20 LN removed recovered potency at a median follow-up of 6 months postoperatively versus 76.7% of patients with 20 LN (278 of 362) (p=.025). There was no significant difference in continence between the groups. CONCLUSIONS: High risk patients should undergo an ex- tended dissection with at least 13 LN removed for accurate staging. Extended PLND with LN yields of 20 is associated with worse potency outcomes. With stage upgrading occurring rarely in low risk patients, ePLND may be counterproductive to the aims of nerve- sparing in this cohort. Source of Funding: None Vol. 187, No. 4S, Supplement, Tuesday, May 22, 2012 THE JOURNAL OF UROLOGY e731